Characteristics of all patients stratified by compensated and recompensated cirrhosis
| Parameter | Compensated | Recompensated |
| n=128 | n=121 | |
| General condition | ||
| Age (years) | 61 (31–82) | 60 (35–77) |
| Sex (male/female) | 92 (72)/36 (28) | 91 (75)/30 (25) |
| Aetiology of cirrhosis (alcohol/viral/other) | 86 (67)/21 (16)/21 (16) | 99 (82)/5 (4)/17 (14) |
| BMI (kg/m2) | 25 (13–45) | 24 (16–41) |
| Baseline scores | ||
| MELD† | 9 (6–25) | 12 (6–21)*** |
| Child-Pugh (A/B/C) | 51 (40)/44 (34)/33 (26) | 46 (38)/26 (21)/49 (41) |
| Child-Pugh | 6 (5–12) | 7 (5–12) |
| CLIF-C AD§ | 47 (34–64) | 52 (33–67)*** |
| Baseline laboratory | ||
| Hb (gL) | 131 (82–171) | 116 (68–169)*** |
| WCC (×109/L)§ | 6.7 (2.4–17.2) | 7.3 (1.8–23.3) |
| Platelets (G/L)‡ | 147 (29–453) | 152 (36–647) |
| Sodium (mmol/L) | 139 (118–146) | 136 (114–145)*** |
| Creatinine (mg/dL) | 0.8 (0.4–2.2) | 0.9 (0.4–2.7)** |
| Bilirubin (mg/dL)† | 0.7 (0.1–12.7) | 1.2 (0.2–6.4)*** |
| ALT (U/L)† | 30 (7–311) | 30 (10–136) |
| Albumin (g/L)† | 35 (15–47) | 28 (18–43)*** |
| INR† | 1.2 (0.9–2.6) | 1.4 (1.0–2.5)*** |
| HVPG | 12 (1.5–28) | 18 (0.5–33)*** |
| Baseline clinical | ||
| Ascites (no/yes) | 128 (100)/0 (0) | 0 (0)/121 (100)*** |
| Oesophageal varices (no - grade I/grade II–III) | 110 (86)/19 (14) | 62 (51)/59 (49)* |
| Outcome | ||
| Mortality 1 year/overall | 9 (7)/29 (23) | 30 (25)*/62 (51)*** |
| Fatal ACLF development 1 year/overall | 4 (3)/14 (11) | 17 (14)/38 (31)* |
| Time to fatal ACLF development (months) | 4 (0–8) | 2 (0–15) |
| Follow-up time (years) | 2 (0–6) | 1 (0–11)*** |
| Biomarkers | ||
| IL-1α | ||
| (Undetectable/detectable) | 97 (76)/31 (24) | 90 (74)/31 (26) |
| Detectable (pg/mL) | 45.6 (9.5–1573.8) | 89.2 (8.5–768.2) |
| IL-1β | ||
| (Undetectable/detectable) | 95 (74)/33 (26) | 77 (63)/45 (37) |
| Detectable (pg/mL) | 73.8 (4.1–622.9) | 70.4 (4.3–1180.5) |
Data expressed as median (range) or absolute frequency (percentage).
***P<0.001, **P<0.01, *P<0.05.
†Data available in 246 patients.
‡Data available in 245 patients.
§Data available in 231 patients.
ACLF, acute-on-chronic liver failure; AD, acute decompensation; ALT, alanine transaminase; BMI, body mass index; CLIF-C, European Foundation for the study of chronic liver failure consortium; Hb, haemoglobin; HVPG, hepatic venous pressure gradient; IL, interleukin; INR, international normalised ratio; MELD, Model for End-Stage Liver Disease; WCC, white cell count.